Annual Accounts Payable
$6.89 M
+$449.00 K+6.97%
December 31, 2023
Summary
- As of February 7, 2025, PBYI annual accounts payable is $6.89 million, with the most recent change of +$449.00 thousand (+6.97%) on December 31, 2023.
- During the last 3 years, PBYI annual accounts payable has fallen by -$5.19 million (-42.95%).
- PBYI annual accounts payable is now -75.12% below its all-time high of $27.69 million, reached on December 31, 2017.
Performance
PBYI Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Payable
$7.51 M
-$5.99 M-44.38%
September 30, 2024
Summary
- As of February 7, 2025, PBYI quarterly accounts payable is $7.51 million, with the most recent change of -$5.99 million (-44.38%) on September 30, 2024.
- Over the past year, PBYI quarterly accounts payable has increased by +$2.45 million (+48.37%).
- PBYI quarterly accounts payable is now -74.00% below its all-time high of $28.88 million, reached on March 31, 2019.
Performance
PBYI Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Payable Formula
Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers
PBYI Accounts Payable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +7.0% | +48.4% |
| 3 y3 years | -43.0% | -23.7% |
| 5 y5 years | -66.7% | -23.7% |
PBYI Accounts Payable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -38.4% | +7.0% | -49.7% | +48.4% |
| 5 y | 5-year | -64.1% | +7.0% | -62.5% | +48.4% |
| alltime | all time | -75.1% | -100.0% | -74.0% | -100.0% |
Puma Biotechnology Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $7.51 M(-44.4%) |
| Jun 2024 | - | $13.50 M(+50.6%) |
| Mar 2024 | - | $8.96 M(+30.1%) |
| Dec 2023 | $6.89 M(+7.0%) | $6.89 M(+36.1%) |
| Sep 2023 | - | $5.06 M(-35.1%) |
| Jun 2023 | - | $7.79 M(-9.2%) |
| Mar 2023 | - | $8.59 M(+33.4%) |
| Dec 2022 | $6.44 M(-42.4%) | $6.44 M(-56.9%) |
| Sep 2022 | - | $14.93 M(+51.7%) |
| Jun 2022 | - | $9.84 M(+32.8%) |
| Mar 2022 | - | $7.41 M(-33.7%) |
| Dec 2021 | $11.17 M(-7.5%) | $11.17 M(-44.3%) |
| Sep 2021 | - | $20.05 M(+79.5%) |
| Jun 2021 | - | $11.17 M(+4.8%) |
| Mar 2021 | - | $10.65 M(-11.8%) |
| Dec 2020 | $12.08 M(-37.0%) | $12.08 M(-3.6%) |
| Sep 2020 | - | $12.53 M(+6.5%) |
| Jun 2020 | - | $11.77 M(-31.9%) |
| Mar 2020 | - | $17.27 M(-10.0%) |
| Dec 2019 | $19.18 M(-7.3%) | $19.18 M(+111.8%) |
| Sep 2019 | - | $9.06 M(-39.9%) |
| Jun 2019 | - | $15.07 M(-47.8%) |
| Mar 2019 | - | $28.88 M(+39.6%) |
| Dec 2018 | $20.68 M(-25.3%) | $20.68 M(+26.4%) |
| Sep 2018 | - | $16.36 M(-26.7%) |
| Jun 2018 | - | $22.34 M(-5.2%) |
| Mar 2018 | - | $23.56 M(-14.9%) |
| Dec 2017 | $27.69 M(+38.2%) | $27.69 M(+56.9%) |
| Sep 2017 | - | $17.64 M(-28.5%) |
| Jun 2017 | - | $24.67 M(+2.9%) |
| Mar 2017 | - | $23.97 M(+19.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2016 | $20.04 M(+12.5%) | $20.04 M(-4.0%) |
| Sep 2016 | - | $20.88 M(-15.2%) |
| Jun 2016 | - | $24.62 M(-0.9%) |
| Mar 2016 | - | $24.84 M(+39.5%) |
| Dec 2015 | $17.80 M(+18.7%) | $17.80 M(+82.0%) |
| Sep 2015 | - | $9.78 M(-6.3%) |
| Jun 2015 | - | $10.44 M(-17.2%) |
| Mar 2015 | - | $12.61 M(-15.9%) |
| Dec 2014 | $15.00 M(+40.3%) | $15.00 M(-18.7%) |
| Sep 2014 | - | $18.45 M(-1.9%) |
| Jun 2014 | - | $18.80 M(+23.7%) |
| Mar 2014 | - | $15.19 M(+42.1%) |
| Dec 2013 | $10.69 M(+2118.3%) | $10.69 M(+9.9%) |
| Sep 2013 | - | $9.73 M(+27.6%) |
| Jun 2013 | - | $7.62 M(+10.7%) |
| Mar 2013 | - | $6.89 M(+1328.8%) |
| Dec 2012 | $482.00 K(+454.0%) | $482.00 K(-52.7%) |
| Sep 2012 | - | $1.02 M(-57.8%) |
| Jun 2012 | - | $2.41 M(+325.3%) |
| Mar 2012 | - | $566.70 K(+551.4%) |
| Dec 2011 | $87.00 K(>+9900.0%) | $87.00 K(+2536.4%) |
| Jun 2011 | - | $3300.00(+37.5%) |
| Mar 2011 | - | $2400.00(>+9900.0%) |
| Dec 2010 | $0.00(-100.0%) | $0.00(0.0%) |
| Sep 2010 | - | $0.00(0.0%) |
| Jun 2010 | - | $0.00(0.0%) |
| Mar 2010 | - | $0.00(-100.0%) |
| Dec 2009 | $2300.00(+4.5%) | $2300.00(>+9900.0%) |
| Sep 2009 | - | $0.00(-100.0%) |
| Jun 2009 | - | $2300.00(+360.0%) |
| Mar 2009 | - | $500.00(-77.3%) |
| Dec 2008 | $2200.00 | $2200.00 |
FAQ
- What is Puma Biotechnology annual accounts payable?
- What is the all time high annual accounts payable for Puma Biotechnology?
- What is Puma Biotechnology annual accounts payable year-on-year change?
- What is Puma Biotechnology quarterly accounts payable?
- What is the all time high quarterly accounts payable for Puma Biotechnology?
- What is Puma Biotechnology quarterly accounts payable year-on-year change?
What is Puma Biotechnology annual accounts payable?
The current annual accounts payable of PBYI is $6.89 M
What is the all time high annual accounts payable for Puma Biotechnology?
Puma Biotechnology all-time high annual accounts payable is $27.69 M
What is Puma Biotechnology annual accounts payable year-on-year change?
Over the past year, PBYI annual accounts payable has changed by +$449.00 K (+6.97%)
What is Puma Biotechnology quarterly accounts payable?
The current quarterly accounts payable of PBYI is $7.51 M
What is the all time high quarterly accounts payable for Puma Biotechnology?
Puma Biotechnology all-time high quarterly accounts payable is $28.88 M
What is Puma Biotechnology quarterly accounts payable year-on-year change?
Over the past year, PBYI quarterly accounts payable has changed by +$2.45 M (+48.37%)